Oppenheimer analyst Jeff Jones raised the firm’s price target on Whitehawk Therapeutics (WHWK) to $7 from $6 and keeps an Outperform rating on the shares after the company provided Q1 financial and business update, with two of three clinical trials planned to begin this year underway. Following a preclinical data reveal at AACR, Oppenheimer sees the Whitehawk candidates HWK-007/-016/-206 as well positioned to address their respective targets in the competitive ADC arena.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WHWK:
- Whitehawk Therapeutics reports Q1 EPS (32c), consensus (33c)
- Whitehawk announces presentation of new preclinical data across ADC portfolio
- Whitehawk Therapeutics management to meet with Oppenheimer
- Whitehawk Therapeutics initiated with an Outperform at Citizens
- Whitehawk Therapeutics presents analysis of MUC16 at SGO